DigiPath Inks Deal with First Medical Marijuana Dispensary in Las Vegas, Euphoria Wellness

May 28, 2015, 06:00 ET from DigiPath, Inc.

LAS VEGAS, May 28, 2015 /PRNewswire/ -- DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc. (OTCBB and OTCQB: DIGPD), has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary. Euphoria Wellness, expected to be the first cannabis dispensary to open in Las Vegas, chose to partner with DigiPath Labs as part of its strategy to set the highest medical marijuana patient safety and education standards in the industry.

"DigiPath Labs will analyze samples of products sold by Euphoria Wellness for unsafe levels of contaminants such as heavy metals, microbes, mycotoxins, pesticides, and solvents, which can exacerbate patient health issues," says Todd Denkin, president of DigiPath Labs. "We will also quantify cannabinoid and terpenoid levels and deliver detailed reports that Euphoria's staff can use to help patients."

Comprehensive cannabis potency testing is critical for patient care. Cannabis is believed to contain over 400 medicinal compounds, most notably cannabinoids and terpenoids, each of which affects the body differently. One compound, THC, is known to induce cancerous cell death. Another compound, CBD, keeps certain cancers from spreading. Different compounds can reduce tissue inflammation, treat epilepsy, and fight methicillin-resistant Staphylococcus aureus (MRSA) infections.

The amount (potency) of each compound present in cannabis medicines can vary widely. Potency is affected by plant genetics, growing conditions, curing and extraction methods, and other factors. Quantifying cannabinoids and terpenoids present in a product is critical to predicting its biological effect on patients.

"Detailed cannabinoid and terpenoid potency reports from DigiPath Labs will enable Euphoria Wellness employees to recommend specific products to patients," says Darlene Purdy, Managing Director at Euphoria Wellness. "We will also educate patients, so that they are able to choose products based on the medicinal properties listed in DigiPath Labs' reports in the future."

About DigiPath, Inc.

DigiPath, Inc., supports the cannabis industry's best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath's four business units are DigiPath Labs, TNM News Corp., DigiPath Corp., and DigiPath U.

For more information, go to www.digipath.com.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include information relating to future events, and future financial and operating performance. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the demand for the Company's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact:

DigiPath, Inc.
Investor Relations
(702)209-2429
IR@digipath.com

Darlene@euphoriawellnessnv.com

Logo - http://photos.prnewswire.com/prnh/20140605/94753

 

SOURCE DigiPath, Inc.



RELATED LINKS

http://www.digipath.biz